Site de l’association HerPAs
 

Publications scientifiques de 2009

2009

Epstein-Barr virus pro­tein EB2 contains an N-ter­mi­nal trans­fe­ra­ble nuclear export signal that pro­mo­tes nucleo­cy­to­plas­mic export by directly bin­ding TAP/NXF1. Juillard F, Hiriart E, Sergeant N, Vingtdeux-Didier V, Drobecq H, Sergeant A, Manet E, Gruffat H. J Virol. 2009 Dec ;83(24):12759-68.

Varicella-zoster virus IE4 pro­tein inte­racts with SR pro­teins and exports mRNAs through the TAP/NXF1 path­way. Ote I, Lebrun M, Vandevenne P, Bontems S, Medina-Palazon C, Manet E, Piette J, Sadzot-Delvaux C. PLoS One. 2009 Nov 18 ;4(11):e7882.

HSV-1-deri­ved ampli­con vec­tors : recent tech­no­lo­gi­cal impro­ve­ments and remai­ning dif­fi­culties—a review. Epstein AL. Mem Inst Oswaldo Cruz. 2009 May ;104(3):399-410. Review.

mRNA trans­la­tion regu­la­tion by the Gly-Ala repeat of Epstein-Barr virus nuclear anti­gen 1. Apcher S, Komarova A, Daskalogianni C, Yin Y, Malbert-Colas L, Fåhraeus R. J Virol. 2009 Feb ;83(3):1289-98.

Infection with herpes sim­plex type 1-based ampli­con vec­tors results in an IRF3/7-depen­dent, TLR-inde­pen­dent acti­va­tion of the innate anti­vi­ral res­ponse in pri­mary human fibro­blasts. Tsitoura E, Thomas J, Cuchet D, Thoinet K, Mavromara P, Epstein AL. J Gen Virol. 2009 Sep ;90(Pt 9):2209-20. Epub 2009 Jun 10.

Progress and pros­pects : bio­lo­gi­cal pro­per­ties and tech­no­lo­gi­cal advan­ces of herpes sim­plex virus type 1-based ampli­con vec­tors. Epstein AL. Gene Ther. 2009 Jun ;16(6):709-15. Epub 2009 Apr 16. Review.

Macroautophagy signa­ling and regu­la­tion. Esclatine A, Chaumorcel M, Codogno P. Curr Top Microbiol Immunol. 2009 ;335:33-70. Review.

Definition of herpes sim­plex virus type 1 helper acti­vi­ties for adeno-asso­cia­ted virus early repli­ca­tion events. Alazard-Dany N, Nicolas A, Ploquin A, Strasser R, Greco A, Epstein AL, Fraefel C, Salvetti A. PLoS Pathog. 2009 Mar ;5(3):e1000340. Epub 2009 Mar 13.

Testing the sus­cep­ti­bi­lity of human her­pes­vi­ru­ses to anti­vi­rals.Agut H, Boutolleau D, Deback C, Bonnafous P, Gautheret-Dejean A.Future Microbiol. 2009 Nov ;4(9):1111-23. Review.

The flexi­ble motif V of Epstein-Barr virus deoxyu­ri­dine 5’-tri­phos­phate pyro­phos­pha­tase is essen­tial for cata­ly­sis.Freeman L, Buisson M, Tarbouriech N, Van der Heyden A, Labbé P, Burmeister WP. J Biol Chem. 2009 Sep 11 ;284(37):25280-9.

Varicella vac­ci­na­tion in Europe - taking the prac­ti­cal approach. Bonanni P, Breuer J, Gershon A, Gershon M, Hryniewicz W, Papaevangelou V, Rentier B, Rümke H, Sadzot-Delvaux C, Senterre J, Weil-Olivier C, Wutzler P. BMC Med. 2009 May 28 ;7:26. Review.

Expression of Epstein-Barr virus EBNA1 pro­tein in Escherichia coli : puri­fi­ca­tion under non­de­na­tu­ring condi­tions and use in DNA-bin­ding stu­dies. Bouallag N, Gaillard C, Maréchal V, Strauss F. Protein Expr Purif. 2009 Sep ;67(1):35-40.

Modulation of B-cell endo­plas­mic reti­cu­lum cal­cium homeo­sta­sis by Epstein-Barr virus latent mem­brane pro­tein-1. Dellis O, Arbabian A, Brouland JP, Kovàcs T, Rowe M, Chomienne C, Joab I, Papp B. Mol Cancer. 2009 Aug 3 ;8:59.

Genetic ana­ly­sis and puta­tive role in resis­tance to anti­vi­rals of the human cyto­me­ga­lo­vi­rus DNA poly­me­rase UL44 pro­ces­si­vity factor. Boutolleau D, Deback C, Bressollette-Bodin C, Conan F, Aït-Arkoub Z, Imbert-Marcille BM, Agut H. Antivir Ther. 2009 ;14(6):847-52.

Different expres­sion of human her­pes­vi­rus-6 (HHV-6) load in whole blood may have a signi­fi­cant impact on the diag­no­sis of active infec­tion. Gautheret-Dejean A, Henquell C, Mousnier F, Boutolleau D, Bonnafous P, Dhédin N, Settegrana C, Agut H. J Clin Virol. 2009 Sep ;46(1):33-6. Epub 2009 Jun 7.

Use of the Roche LightCycler 480 system in a rou­tine labo­ra­tory set­ting for mole­cu­lar diag­no­sis of oppor­tu­nis­tic viral infec­tions : Evaluation on whole blood spe­ci­mens and pro­fi­ciency panels. Deback C, Géli J, Aït-Arkoub Z, Angleraud F, Gautheret-Dejean A, Agut H, Boutolleau D. J Virol Methods. 2009 Aug ;159(2):291-4.

Length varia­bi­lity of telo­me­ric repeat sequen­ces of human her­pes­vi­rus 6 DNA. Achour A, Malet I, Deback C, Bonnafous P, Boutolleau D, Gautheret-Dejean A, Agut H. J Virol Methods. 2009 Jul ;159(1):127-30.

Phosphatidylinositol 3-kinase/Akt path­way tar­gets ace­ty­la­tion of Smad3 through Smad3/CREB-bin­ding pro­tein inte­rac­tion : contri­bu­tion to trans­for­ming growth factor beta1-indu­ced Epstein-Barr virus reac­ti­va­tion.Oussaief L, Hippocrate A, Ramirez V, Rampanou A, Zhang W, Meyers D, Cole P, Khelifa R, Joab I. J Biol Chem. 2009 Sep 4 ;284(36):23912-24. Epub 2009 Jul 9.

Activation of the lytic pro­gram of the Epstein-Barr virus in Burkitt’s lym­phoma cells leads to a two steps down­re­gu­la­tion of expres­sion of the proa­pop­to­tic pro­tein BimEL, one of which is EBV-late-gene expres­sion depen­dent. Oussaief L, Hippocrate A, Clybouw C, Rampanou A, Ramirez V, Desgranges C, Vazquez A, Khelifa R, Joab I. Virology. 2009 Apr 25 ;387(1):41-9.

Contribution of human her­pes­vi­rus 6 (HHV-6) viral load in whole blood and serum to inves­ti­gate inte­gra­ted HHV-6 trans­mis­sion after hae­ma­to­poie­tic stem cell trans­plan­ta­tion. Jeulin H, Salmon A, Gautheret-Dejean A, Agut H, Bordigoni P, Fortier B, Venard V. J Clin Virol. 2009 May ;45(1):43-6. Epub 2009 Mar 24.

Utilization of micro­sa­tel­lite poly­mor­phism for dif­fe­ren­tia­ting herpes sim­plex virus type 1 strains. Deback C, Boutolleau D, Depienne C, Luyt CE, Bonnafous P, Gautheret-Dejean A, Garrigue I, Agut H. J Clin Microbiol. 2009 Mar ;47(3):533-40.

Resistance pat­tern of cyto­me­ga­lo­vi­rus (CMV) after oral val­gan­ci­clo­vir the­rapy in trans­plant reci­pients at high-risk for CMV infec­tion. Boutolleau D, Deback C, Bressollette-Bodin C, Varnous S, Dhedin N, Barrou B, Vernant JP, Gandjbakhch I, Imbert-Marcille BM, Agut H. Antiviral Res. 2009 Feb ;81(2):174-9.

The Marek’s disease virus (MDV) pro­tein enco­ded by the UL17 ortho­log is essen­tial for virus growth. Chbab N, Chabanne-Vautherot D, Francineau A, Osterrieder O, Denesvre C, Vautherot JF. Veterinary Research, 2009 ; 40 : 28.

Inhibition of Epstein-Barr virus repli­ca­tion by small inter­fe­ring RNA tar­ge­ting the Epstein-Barr virus pro­tease gene. Larrat S, Morand P, Bas A, Vigne S, Crance JM, Boyer V, Nicod S, Grossi L, Buisson M, Burmeister WP, Seigneurin JM, Germi R. Antivir Ther. 2009 ;14(5):655-62.

A bridge cros­ses the active-site canyon of the Epstein-Barr virus nuclease with DNase and RNase acti­vi­ties. Buisson M, Géoui T, Flot D, Tarbouriech N, Ressing ME, Wiertz EJ, Burmeister WP. J Mol Biol. 2009 Aug 28 ;391(4):717-28.

Probing PML body func­tion in ALT cells reveals spa­tio­tem­po­ral requi­re­ments for telo­mere recom­bi­na­tion. Draskovic I, Arnoult N, Steiner V, Bacchetti S, Lomonte P, Londoño-Vallejo A. Proc Natl Acad Sci U S A. 2009 Sep 15 ;106(37):15726-31

Translation of intron­less RNAs is stron­gly sti­mu­la­ted by the Epstein-Barr virus mRNA export factor EB2. Ricci EP, Mure F, Gruffat H, Decimo D, Medina-Palazon C, Ohlmann T, Manet E. Nucleic Acids Res. 2009 Aug ;37(15):4932-43.

Blood dif­fu­sion and Th1-sup­pres­sive effects of galec­tin-9-contai­ning exo­so­mes relea­sed by Epstein-Barr virus-infec­ted naso­pha­ryn­geal car­ci­noma cells. Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le Moulec S, Guigay J, Hirashima M, Guemira F, Adhikary D, Mautner J, Busson P. Blood. 2009 Feb 26 ;113(9):1957-66.

Strong cor­re­la­tions of anti-Viral Capsid Antigen anti­body levels in first-degree rela­ti­ves from fami­lies with Epstein Barr Virus-rela­ted lym­pho­mas. Besson C, Amiel C, Le-Pendeven C, Plancoulaine S, Bonnardel C, Ranque B, Abbed K, Brice P, Fermé C, Carde P, Hermine O, Raphael M, Bresson JL, Nicolas JC, Gessain A, deThe G, Abel L. J Infect Dis 2009 ;199:1121-7.

c-Myc and Rel/NF-kappaB are the two master trans­crip­tio­nal sys­tems acti­va­ted in the latency III pro­gram of Epstein-Barr virus-immor­ta­li­zed B cells. Faumont N, Durand-Panteix S, Schlee M, Grömminger S, Schuhmacher M, Hölzel M, Laux G, Mailhammer R, Rosenwald A, Staudt LM, Bornkamm GW, Feuillard J. J Virol. 2009 May ;83(10):5014-27.

Interaction of Epstein-Barr virus BZLF1 C-ter­mi­nal tail struc­ture and core zipper is requi­red for DNA repli­ca­tion but not for pro­mo­ter tran­sac­ti­va­tion.McDonald CM, Petosa C, Farrell PJ. J Virol. 2009 Apr ;83(7):3397-401.

The gene­tic diver­sity of three pecu­liar popu­la­tions des­cen­ding from the slave trade : Gm study of Noir Marron from French Guiana. Brucato N, Tortevoye P, Plancoulaine S, Guitard E, Sanchez-Mazas A, Larrouy G, Gessain A, Dugoujon JM. C R Biol. 2009 Oct ;332(10):917-26.

EBV-asso­cia­ted mono­nu­cleo­sis does not induce long-term global defi­cit in T-cell res­pon­si­ve­ness to IL-15. Giron-Michel J, Ménard F, Negrini S, Devocelle A, Azzarone B, BessonC. Blood 2009 ;113:4541-7.

Methylation-depen­dent bin­ding of the epstein-barr virus BZLF1 pro­tein to viral pro­mo­ters. Dickerson SJ, Xing Y, Robinson AR, Seaman WT, Gruffat H, Kenney SC. PLoS Pathog. 2009 Mar ;5(3):e1000356.

Characterization of the ubi­nu­clein pro­tein as a new member of the nuclear and adhe­sion com­plex com­po­nents (NACos). Aho S, Lupo J, Coly PA, Sabine A, Castellazzi M, Morand P, Sergeant A, Manet E, Boyer V, Gruffat H. Biol Cell. 2009 Jun ;101(6):319-34.